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Psoriasis in a Nationwide Cohort Study of
Patients with Celiac Disease
Jonas F. Ludvigsson1,2, Bernt Lindelo¨f3, Fabiana Zingone4 and Carolina Ciacci5
Earlier studies on the association between celiac disease (CD) and psoriasis show contradictory results. The
purpose of this study was to assess the risk of psoriasis in patients with biopsy-verified CD. Through 28
pathology departments in Sweden, we identified individuals with CD diagnosed between 1969 and 2008 (Marsh
3: villous atrophy; n¼ 28,958 unique individuals). We then used Cox regression to compare individuals with CD
with 143,910 sex- and age-matched controls regarding their risk of psoriasis. CD was a risk factor for future
psoriasis (hazard ratio (HR)¼ 1.72; 95% confidence interval (CI)¼ 1.54–1.92; during follow-up, 401 individuals
with CD and 1,139 controls had a diagnosis of psoriasis). The absolute risk of future psoriasis in patients with CD
was 135/100,000 person-years (excess risk¼ 57/100,000). In all, 42% of all psoriasis in patients with CD could be
attributed to the underlying CD. Moreover, in children we saw a positive association between CD and psoriasis
(HR¼ 2.05; 95% CI¼ 1.62–2.60). The association between CD and psoriasis seems to be independent of a
temporal relationship, as we also found a positive association between CD and psoriasis before CD diagnosis
(odds ratio¼ 1.91; 95% CI¼ 1.58–2.31). In conclusion, individuals with CD were at increased risk of psoriasis both
before and after CD diagnosis.
Journal of Investigative Dermatology (2011) 131, 2010–2016; doi:10.1038/jid.2011.162; published online 9 June 2011
INTRODUCTION
Celiac disease (CD) is an immune-mediated disease that occurs
in B1% of the western population. This disease is triggered
by gluten exposure in genetically sensitive individuals. Earlier
research suggests that CD is associated with a number of
autoimmune diseases (Collin et al., 2002; Ludvigsson et al.,
2006; Elfstrom et al., 2007, 2008; Neuhausen et al., 2008).
Psoriasis is a chronic autoimmune skin disease. Common
symptoms include red scaly patches on the skin. Some
patients have affected nails and joints (psoriatic arthritis).
Earlier research has suggested a link between CD and
psoriasis (Ojetti et al., 2003; Birkenfeld et al., 2009; Tursi
et al., 2010), but such an association has also been
questioned (Collin and Reunala, 2003) and several papers
suffer from limitations including small numbers of patients
with CD (Tursi et al., 2010) and lack of controls (Tursi et al.,
2010). A recent paper also found a higher prevalence of
CD-associated antibodies in patients with psoriasis (Singh
et al., 2010; although data are conflicting; Kia et al., 2007),
and some patients with psoriasis and antigliadin antibodies
will improve on a gluten-free diet despite the absence of
villous atrophy (VA) on biopsy (Michaelsson et al., 2000;
Addolorato et al., 2003). It may also be that disease activity in
psoriasis correlates with levels of CD-associated antibodies
(Lindqvist et al., 2002; Woo et al., 2004). In a recent large
population-based case–control study, Birkenfeld et al. (2009)
reported that patients with psoriasis had more CD than
matched controls, but the prevalence of CD in that study was
only 0.11%, whereas it is generally agreed that CD occurs in
about 1% of the normal population (Dube et al., 2005).
The main objective of this study was to examine the
prevalence of psoriasis in a nationwide population-based
sample of patients with biopsy-verified CD.
RESULTS
Background data
Some 60% of participants were female (Table 1), and the
median age at study entry was 30 years. Median follow-up
was 9 years.
The median age at first diagnosis of psoriasis was 52 years
in individuals with CD and 55 years in controls. The median
duration from study entry until first recorded diagnosis
of psoriasis was 7 years in both those with CD and in their
controls.
CD and risk of psoriasis
During the study period, 401 individuals with CD and 1,139
controls developed psoriasis. This corresponded to a hazard
ratio (HR) of 1.72 (95% confidence interval (CI)¼ 1.54–1.92;
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Table 2). The absolute risk of future psoriasis in patients
with CD was 135/100,000 person-years, with an excess risk
of 57/100,000. Some 42% of all psoriasis in patients with CD
could be attributed to the underlying CD (Table 2).
The HR for psoriasis remained around 1.7 also when
we excluded the first year of follow-up (HR¼ 1.71; 95%
CI¼1.52–1.92). Even 5 years after CD diagnosis did we see a
more than 60% increased risk for psoriasis in patients with
CD (Table 2).
Adjustment for type 1 diabetes, rheumatoid arthritis, and
autoimmune thyroid disease did not affect the risk estimates
(adjusted HR¼ 1.70; 95% CI¼1.52–1.91). Neither did
adjustment for country of birth (adjusted HR¼1.70; 95%
CI¼1.52–1.90) nor education (adjusted HR¼ 1.72; 95%
CI¼1.54–1.93) influence the risk estimates. We found similar
risk estimates in men and women (Table 3). Interaction tests
revealed that the risk of psoriasis in CD did not differ
significantly according to sex (P¼0.238) or according to age
at biopsy (P¼0.241). Children (diagnosed o20 years of age)
with CD were at a statistically significantly increased risk
of later psoriasis (HR¼ 2.05; 95% CI¼1.62–2.60; Table 3).
Also when we excluded individuals with any skin disease
(psoriasisþ other skin disease), CD was still associated with
future psoriasis (HR¼1.69; 95% CI¼1.50–1.91).
Psoriasis confirmed by psoriatic medication
Individuals with CD were at a 2-fold increased risk of having
a diagnosis of psoriasis confirmed by a record of psoriatic
medication. However, because of few positive events, this
association was not statistically significant (four individuals
with CD versus nine controls fulfilled our criteria; HR¼2.06;
95% CI¼ 0.63–6.70; P¼ 0.231).
Comparison with other individuals undergoing small intestinal
biopsy
Compared with individuals undergoing small intestinal
biopsy but not having VA, individuals with CD were at no
increased risk of psoriasis (compared with inflammation
(Marsh 1–2): HR¼0.96; 95% CI¼ 0.71–1.30 and compared
with those with normal mucosa (Marsh 0) but positive
CD serology: HR¼0.99; 95% CI¼ 0.83–1.18).
Previous psoriasis and risk of later CD
Out of 29,096 individuals with CD, 137 (0.47%) had a
previous diagnosis of psoriasis versus 341/144,522 (0.23%).
Hence, we found a positive association between CD and
psoriasis also before CD diagnosis. A previous psoriasis
diagnosis increased the risk for future CD (odds ratio¼1.91;
95% CI¼ 1.58–2.31).
Table 1. Characteristics of study participants
Matched
controls
Celiac
disease
Total 143,910 28,958
Age at study entry, years
(median, range)
0–95 (30) 0–95 (30)
Attained age, years
(median, range)
1–105 (40) 1–100 (41)
Age 0–19 years (%) 58,815 (40.9) 11,793 (40.7)
Age 20–39 years (%) 26,305 (18.3) 5,295 (18.3)
Age 40–59 years (%) 32,021 (22.3) 6,418 (22.2)
Age X60 years (%) 26,769 (18.6) 5,452 (18.8)
Entry year (median, range) 1969–2008 (1998) 1969–2008 (1998)
Follow-upa, years
(median, range)
0–40 (9) 0–40 (9)
Follow-upa, years (mean±SD) 10.4±6.4 10.2±6.4
Females (%) 89,192 (62.0) 17,927 (61.9)
Males (%) 54,718 (38.0) 11,031 (38.1)
Calendar year
1989 20,344 (14.1) 4,097 (14.1)
1990–99 59,747 (41.5) 12,035 (41.6)
2000 63,819 (44.3) 12,826 (44.3)
Country of birth
Nordicb 135,703 (94.3) 28,010 (96.7)
Outside the Nordic region 8,207 (5.7) 948 (3.3)
Rheumatoid arthritis 830 (0.6) 287 (1.0)
Autoimmune thyroid disease 319 (0.2) 200 (0.7)
Type 1 diabetes 531 (0.4) 921 (3.2)
aFollow-up time until diagnosis of psoriasis, death from other cause,
emigration, or 31 December 2008. In controls, follow-up can end through
small intestinal biopsy.
bSweden, Denmark, Finland, Norway, and Iceland.
Table 2. Risk of psoriasis based on follow-up time in 28,958 individuals with celiac disease
Follow-up
Observed
events
Expected
events HR; 95% CI P-value
Absolute risk/
100,000 PYAR
Excess risk/
100,000 PYAR
Attributable
percentage
All 401 233 1.72; 1.54–1.92 o0.001 135 57 41.9
o1 Year 25 13 1.89; 1.21–2.94 0.005 87 41 47.0
1–4.99 127 68 1.87; 1.53–2.29 o0.001 124 58 46.6
5+ 249 152 1.63; 1.42–1.88 o0.001 150 58 38.8
Abbreviations: CI, confidence interval; HR, hazards ratio; PYAR, person-years at risk.
Reference is general population comparator cohort.
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DISCUSSION
To our knowledge, this is the largest study to date on CD and
psoriasis. It was based on almost 29,000 individuals with
biopsy-verified CD identified from 28 Swedish pathology
departments. Psoriasis was defined according to outpatient or
inpatient International Classification of Disease (ICD) codes.
Earlier validation has shown high validity for most chronic
conditions in the Swedish national patient register (Ragnarson
Tennvall et al., 2000; Hultgren et al., 2001; Smith et al.,
2009). Almost all Swedish health care is publicly funded,
guaranteeing a virtually 100% complete follow-up through
linkage with the unique personal identity number.
Comparison with earlier literature
As opposed to the recent Israeli study by Birkenfeld et al.
(2009; with an odds ratio of 2.73), our risk estimates were
consistently below two. One explanation for our lower risk
estimates deals with our ascertaining CD through pathology
databases. Ascertaining CD through pathology databases
has previously yielded lower risk estimates than similar
studies using the inpatient registers to identify CD (compare,
e.g., relative risks of death in CD: Ludvigsson et al. (2009c):
1.39 with Peters et al. (2003): 2.0. Another, perhaps more
likely, explanation of our lower risk estimates is the rarity of
diagnosed CD in Israel. It is possible that most patients in that
study suffered from (severe) symptomatic CD (0.11% of
controls had CD (Birkenfeld et al., 2009), whereas 29,000
patients with CD in the current study equal around 0.3% of
the Swedish population).
Although we did not screen the entire Swedish population
for CD, our data indicate a 2-fold increased risk of CD in
patients with previous psoriasis. This is consistent with recent
data from Montesu et al. (2011). In their study, 2% of
psoriasis patients had CD (as compared with expected 1%
(Dube et al., 2005)), although none of their controls showed a
positive CD serology (Montesu et al., 2011). Woo et al.
(2004) in a series of 130 psoriatic patients found 3 (2.3%)
patients with VA, and also reported that positive CD serology
correlated with increased disease activity in psoriasis. An
Italian study reported that 4/92 (4.3%) patients with psoriasis
versus 0/90 controls had CD (Ojetti et al., 2003); and a
Swedish study that 5/114 (4.4%) individuals with psoriatic
arthritis had CD (the Swedish study used no controls;
Lindqvist et al., 2002). Meanwhile, an Iranian study failed
to show an increased prevalence of CD in 328 patients with
psoriasis (Zamani et al., 2010).
Our study was based on histopathological evidence of CD,
and is therefore difficult to compare with studies on psoriasis
and CD serology (Michaelsson et al., 1993; Kia et al., 2007;
Damasiewicz-Bodzek and Wielkoszynski, 2008; Sultan et al.,
2010). Studies on CD serology in psoriatic patients have been
both positive (Michaelsson et al., 1993; Damasiewicz-
Bodzek and Wielkoszynski, 2008) and negative (Kia et al.,
2007; Sultan et al., 2010). Heterogeneity can probably
be explained through the low positive predictive value of
CD serology (Hopper et al., 2007), especially antigliadin
antibodies (43% in the paper by Hadithi et al. (2007)).
Mechanisms
Several mechanisms might explain the positive association
between CD and psoriasis described in this study. First,
malabsorption in CD, both before and after diagnosis,
increases the risk of vitamin D deficiency (Bode et al.,
1991) and besides the gluten-free diet is often low in vitamin
Table 3. Risk of psoriasis according to characteristics of patients with celiac disease
Subgroup
Observed
events
Expected
events HR; 95% CI P-value
Absolute risk/
100,000 PYAR
Excess risk/
100,000 PYAR
Attributable
percentage
Sex
Males 156 84 1.86; 1.55–2.24 o0.001 140 65 46.3
Females 245 149 1.64; 1.42–1.89 o0.001 132 52 39.0
Age
o20 years 96 47 2.05; 1.62–2.60 o0.001 71 37 51.3
20–39 years 86 47 1.84; 1.44–2.35 o0.001 159 73 45.7
40–59 years 148 95 1.56; 1.30–1.88 o0.001 218 78 36.0
60+ years 71 45 1.58; 1.21–2.07 0.001 177 65 36.7
Calendar period
1989 62 42 1.46; 1.10–1.95 0.010 76 24 31.6
1990–1999 213 116 1.83; 1.57–2.14 o0.001 143 65 45.4
2000–2008 126 75 1.69; 1.39–2.06 o0.001 192 79 40.8
Abbreviations: CI, confidence interval; HR, hazards ratio; PYAR, person-years at risk.
Reference is general population comparator cohort.
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D (Kupper, 2005). Vitamin D deficiency predisposes to
psoriasis, and exposure to sun light as well a administration of
vitamin D analog creams have a beneficial effect on psoriasis
(Lehmann, 2009). Second, in patients with CD (before
and after diagnosis), exposure to gliadin will trigger a
CD4þ T-cell response and a cascade of proinflammatory
cyotkines such as IFN-g (Nilsen et al., 1998). The increased
number of T cells in the blood may affect also the dermis and
epidermis, thereby stimulating the development of psoriasis
(Monteleone et al., 2010). The psoriatic plaque is character-
ized by a marked infiltration of activated CD4þ and CD8þ
T cells. CD4þ T cells infiltrate mainly the dermis, whereas
CD8þ T cells are present in the epidermis (Nestle et al.,
2009). Third, shared genetic factors could have a role. Liu et al.
(2008) first described a psoriatic locus on chromosome 4q27
that harbors both IL-2 and IL-21. This locus (IL2/21) has
previously been linked to CD (van Heel et al., 2007; Adamovic
et al., 2008). A fourth potential mechanism regards the increase
in intestinal permeability (Abenavoli et al., 2009) seen in
patients with psoriasis (Humbert et al., 1991). Affected
intestinal permeability is a hallmark of CD. Still, further studies
are needed to explore the underlying mechanism for the
positive association between CD and psoriasis, as our study
lacks individual-based immunological and genetic data.
Strengths and limitations
This study was based on almost 29,000 patients with CD.
The large numbers allowed for important subanalyses and, for
instance, we were able to examine the relationship between
CD and psoriasis in children. Although we cannot rule out
that our HR is slightly inflated by ascertainment bias, such
bias is unlikely to fully explain the positive association seen
in this study, as the risk increase remained more than 5 years
after CD diagnosis. VA has been the gold standard for CD
diagnosis in Sweden since the 1970s (Cavell et al., 1992;
Stenhammar et al., 2006), and in a recent survey, 96% of
adult gastroenterologists and 100% of pediatricians perform a
small intestinal biopsy in at least 90% of patients with
suspected CD before assigning a diagnosis of CD (Ludvigsson
et al., 2009b). When we reviewed 114 randomly selected
patient charts from patients with VA, 108 (95%) had CD.
Moreover, when we manually reviewed more than 1,500
biopsy reports, we found that other diagnoses than CD
seldom explain VA (0.3% of those with VA had inflammatory
bowel disease and 0.2% suffered from Helicobacter pylori;
Ludvigsson et al., 2009b). Although we did not require a
positive CD serology for our CD diagnosis, 88% of validated
individuals with VA and available serology data had positive
CD serology at the time of biopsy (Ludvigsson et al., 2009b).
We would also like to underline our use of different
reference groups. Compared with individuals with inflamma-
tion or normal mucosa but positive CD serology, those with
CD were at no increased risk of psoriasis. This suggests that
the risk increase for psoriasis may not require severe mucosal
abnormalities but that microscopic inflammation including
intraepithelial lymphocytosis may be sufficient. Moreover,
we were able to link our data to the Swedish Prescribed Drug
Register. Although that register covers only a short time span,
the relative risk in that analysis (HR¼2.06) indicates that the
positive association seen in our main analysis is not a chance
finding. However, the small number of individuals with
medication registered in the Prescribed Drug Register meant
that the association was not statistically significant.
This study also had some weaknesses. We were unable to
measure the activity of psoriasis. We did not have access
to smoking data. Smoking is, however, inversely related
to CD (Snook et al., 1996; if at all related (Ludvigsson et al.,
2005)), but positively associated with psoriasis (Naldi et al.,
2005; Jankovic et al., 2009). Hence, confounding by smoking
cannot explain the positive association between CD and
psoriasis seen in this study. Neither did we have data on
alcohol consumption. Alcohol consumption has been linked
to psoriasis (Poikolainen et al., 1990) but not to CD
(McMillan et al., 1998). When Zingone et al. (2009)
examined risk factors for psoriasis in patients with CD, they
found that the risk of psoriasis was higher in patients with
undiagnosed CD and a high body mass index, as opposed to
those with normal body mass index. Unfortunately the
current study did not have access to data on body mass
index. Finally we had no data on dietary compliance and
vitamin D status. This means that we were unable to estimate
the importance of adhering to a gluten-free diet for the risk
of psoriasis, and what role vitamin D status may have had for
the development of psoriasis.
In conclusion, we found an increased risk of psoriasis in
patients with CD. This risk increase was seen both before and
after diagnosis of CD. It was seen in all age strata and
remained more than 5 years after CD diagnosis.
MATERIALS AND METHODS
We linked nationwide biopsy data on CD with inpatient and
outpatient data on psoriasis. Through Cox regression, we estimated
HRs for psoriasis in the Swedish Patient Register and in a subanalysis
also when the diagnosis of psoriasis was confirmed by a record of
medication in the Swedish Prescribed Drug Register.
Data collection
Between October 2006 and February 2008, we collected computer-
ized biopsy data from all Swedish pathology departments (n¼ 28),
with biopsies performed between 1969 and 2008. Data from
biopsies included arrival date of biopsies, personal identity number
(Ludvigsson et al., 2009d), morphology, and topography (duodenum
and jejunum).
We defined CD as having VA (Marsh 3) according to the Swedish
SnoMed classification (for a translation of the SnoMed classification,
please see the Supplementary Appendix online).
We did not request a positive CD serology for the diagnosis of
CD, although earlier validation of a subset of randomly selected
individuals with CD has shown that 88% had positive CD serology at
time of biopsy (Ludvigsson et al., 2009b). Of individuals with VA and
available data, 2,268/3,374 (67.2%) had positive IgA tissue
transglutaminase/endomysial, whereas 1,106 (32.8%) were positive
for IgA Gliadin or IgG tissue transglutaminase/endomysial/gliadin.
In the current study, 95% of individuals with VA (108/114) had
CD according to patient charts (Ludvigsson et al., 2009b) and 79% of
individuals had gastrointestinal symptoms before biopsy.
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Controls
For each individual undergoing biopsy, Statistics Sweden selected
up to five controls matched for age, sex, calendar period, and
county from the Total Population Register. Controls were sampled
from all Swedish residents who had no previous duodenal/
jejunal biopsy.
Secondary reference groups of individuals undergoing biopsy
For comparative reasons, we also collected biopsy data of patients
with inflammation without VA (Marsh 1–2) and normal mucosa
but positive CD serology (Marsh 0 with positive IgA/IgG for
antigliadin, endomysial, or tissue transglutaminase) (Ludvigsson
et al., 2009a). These two cohorts were used as secondary reference
groups. In the most commonly used Swedish histopathology
classification (Committee for Quality and Standardization), inflam-
mation is equal to intraepithelial inflammation. More information on
the data collection method has been published in two validation
papers (Ludvigsson et al., 2009a, b).
Exclusions
After matching to (primary) controls, we excluded 174 individuals
where the biopsy (VA, inflammation, or normal mucosa) could
potentially have been from the ileum, those with no matched
control, or those who lacked a serial number from Statistics
Sweden (n¼ 35). We excluded 247 controls because of data
irregularities and an additional 921 controls who could not
be matched. The remaining individuals are identical to those in
our study on mortality in CD (Ludvigsson et al., 2009c).
Additional exclusions are shown in Figure 1. For the purpose of
our initial analyses, we excluded anyone with a diagnosis of
psoriasis before study entry (date of first biopsy). As each stratum
(one individual with CD and his/her controls) was analyzed
separately, a number of controls were excluded as their index
individual with CD had been excluded.
The main analyses of this paper were based on 28,958
individuals with CD and 143,910 general population controls.
The secondary reference groups consisted of 13,223 individuals
with inflammation and 3,686 individuals with normal mucosa but
positive CD serology.
Outcome
Our main outcome was a diagnosis of psoriasis defined according to
relevant ICD codes (ICD-7 (1964–1968, code 706.0), ICD-8
(1969–1986, code 696.00-19), ICD-9 (1987–1996 code 696A-B)
and ICD-10 (1997-, code L40); Ji et al., 2009) in the Swedish Patient
Register. This register contains both inpatient data (from 1964 and
nationwide since 1987) and hospital outpatient data (since 2001 and
nationwide from the start).
In a subanalysis, we examined the risk of having a diagnosis of
psoriasis confirmed by a record of psoriatic medicine (including
biological treatments) in the Swedish Prescribed Drug Register. This
register was initiated in mid-2005 and contains outpatient data on
medication according to relevant Anatomical Therapeutic Chemical
Classification System codes (see Supplementary Appendix online).
When we only included individuals with a follow-up until, at least,
1 July 2005 this subanalysis was based on 26,219 individuals with
CD and 132,007 controls.
Statistics
Prospective analyses: CD and risk of later psoriasis. We used
internal stratified Cox regression to estimate HRs for psoriasis. The
internal stratification means that the index individual was only
compared with his or her controls within the same stratum and then
a summary risk estimate was calculated. The proportional hazards
assumption was tested through plotting log-minus-log curves.
Follow-up started on the date of the first biopsy with VA and the
corresponding date in matched controls. Follow-up ended with
psoriasis diagnosis, death, emigration, or on 31 December 2008,
whichever happened first. Attributable risks (%) were calculated as
(1-1/HR), and absolute risk as number of incident cases with
psoriasis divided by years of follow-up.
In a priori subanalyses, we examined the risk of psoriasis by
follow-up period, sex, age, and calendar year at CD diagnosis.
Incidence rates were calculated as the number of first recorded
psoriasis diagnoses per person-years at risk.
In a subanalysis, we also adjusted for type 1 diabetes mellitus,
rheumatoid arthritis, autoimmune thyroid disease (see Supplemen-
tary Appendix online for ICD codes), level of education, and country
of birth (Nordic country vs non-Nordic country). Individualized data
Undergoing biopsy, n = 46,330
(29,148 with CD)
(13,446 with inflammation, #)
(3,736 with normal mucosa, §)
Controls, n = 229,800
n = 46,121
(Patients undergoing biopsy)
n = 228,632
(Controls to patients undergoing biopsy)
Controls to CD patients, n = 144,522
Controls, n = 143,910 Psoriasis before biopsy, n = 340Strata without CD cases, n = 272*
CD, n = 29,096
CD, n = 28,958
Psoriasis before biopsy, n = 137
Strata without controls, n = 1
First exclusions, n = 209
Biopsy from ileum, n = 174
Lacking serial number, n = 8
Lacking matched control, n = 27
First exclusions, n = 1,168
Not possible to match, n = 921
Data irregularities, n = 247
Figure 1. Flow chart of study participants. The symbol ‘*’ denotes that 272 controls were excluded because their matched individual undergoing biopsy had
been excluded (and all analyses were matched on strata, see Materials and Methods). The symbol ‘#’ denotes Marsh pathology grades 1–2 and ‘y’ denotes Marsh
pathology grade 0 in individuals with positive celiac disease (CD) serology (antigliadin, antiendomysial, or antitransglutaminase antibodies).
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on education were retrieved from Statistics Sweden and grouped
according to seven pre-defined levels. In a post hoc analysis, we
excluded all individuals with any skin disease before study entry (this
analysis was based on 27,051 individuals with CD and 138,808
matched reference individuals).
Finally, we examined the risk of psoriasis in individuals with CD
compared with the risk in secondary reference groups undergoing
small intestinal biopsy but not having VA.
Case–control study: previous psoriasis and risk of later CD. In
a case–control study we used conditional logistic regression to
examine the relationship between previous psoriasis and later CD.
Moreover, in this analysis did we define psoriasis according to
relevant ICD codes. We based this analysis on 29,096 individuals
with CD and 144,522 controls matched for sex, age, calendar
period, and county (Figure 1). We then looked at the number
of individuals with a previous diagnosis of psoriasis.
We used SPSS 18.0 (Chicago, IL) to perform all analyses. Relative
risks with 95% CIs that did not include 1 were regarded as statistically
significant.
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